Stock Evaluator: Twist Bioscience Corporation (TWST)

Twist Bioscience Corporation TWST

$91.55 0.22 0.24%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,494,174
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Commentary & Analysis


Financial Summary

Share Statistics TWST Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $5,700.9 $252.6 69%
Shares Out (Mil) 61.7 52.3 53%
Institutional Ownership 97.9% 92.1% 76%
Float (Mil) 55.4 40.2 50%
Beta 2.23 0.95 94%
Avg Daily Volume (000s) 1,256 455 75%
Price Change
(52-week)
163.6% 52.9% 96%
Growth TWST Industry
Median
Percentile
(All Stocks)
Sales (5yr) 33.1% 13.6% 91%
Net Income (5yr) 11.1% (9.9%) 57%
EPS (5yr) 18.3% 16.0% 65
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (21.1%) (15.6%) 31%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 4
Current EPS ($0.180) ($0.770) ($0.850)
Month Ago EPS ($0.180) ($0.770) ($0.763)
# Rev Up 0 1 0
# Rev Down 1 0 0
Three Months Ago EPS ($0.490) ($1.970) ($1.885)
Year/Year Chg (74.8%) (40.7%) (97.9%)
Financials TWST Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $410 $38 39%
Net Income (TTM) (Mil) ($81) ($43) 12%
EPS (TTM) ($1.337) ($1.600) 19%
Operating Cash Flow (TTM) (Mil) ($56) ($31) 9%
Net Cash Flow (TTM) (Mil) ($88) $5 15%
Long-Term Debt (Q1) (Mil) $100 $5 45%
Enterprise Value (Q1) (Mil) $3,423 $180 57%
Valuation TWST Industry
Median
Percentile
(All Stocks)
P/B 12.51 2.56 92%
P/E na 19.0 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios TWST Industry
Median
Percentile
(All Stocks)
Gross Margin 52.1% 63.8% 64%
Net Margin (19.8%) (67.3%) 17%
ROA (12.8%) (49.8%) 24%
ROE (18.2%) (55.5%) 24%
Liabilities to Assets 32.7% 30.3% 24%
F-Score 4 3 34%

Twist Bioscience Corporation did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors